alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 99.1



GENAERA CORPORATION



CERTIFICATION OF

CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Genaera Corporation (the Company) on Form 10-Q for the three-month period ended March 31, 2003 as
filed with the Securities and Exchange Commission on the date hereof (the Report), I, Roy C. Levitt, M.D., President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section
906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) |  | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
| | --- |  | ---------------------------------------------------------------------------------------------------------------------------------



| | (2) |  | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                         
|---------------------------------------------------------
|/s/    ROY C.
LEVITT                                     
|Roy C. Levitt, M.D. President and Chief Executive Officer



May 8, 2003
* Pursuant to 5TH CIR. R. 47.5, the Court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5TH CIR. R. 47.5.4.

UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

____________________

No. 98-50037

Summary Calendar

____________________

BARBARA JO WEBB,

Plaintiff-Appellant,

versus

WAYNE SCOTT, DIRECTOR, TEXAS DEPARTMENT OF CRIMINAL JUSTICE,

INSTITUTIONAL DIVISION; PAMELA WILLIAM, Warden of Hobby Unit,

Marlin, Texas; KENNETH SELLER, Correctional Officer #3 at Texas

Department of Criminal Justice Institutional Division, Hobby

Unit,

Defendants-Appellees.

_________________________________________________________________

Appeal from the United States District Court,

for the Western District of Texas

(USDC No. W-97-CV-242)

_________________________________________________________________

December 3, 1998

Before KING, BARKSDALE, and STEWART, Circuit Judges.

PER CURIAM:*

Barbara Jo Webb, Texas inmate #335682, appeals, pro se, the

denial of her motion for leave to proceed in forma pauperis (IFP)

in the district court and the dismissal of her complaint based on

her inability to pay the initial partial filing fee. (Webb’s
2

motions for supplementation of the record and for discovery are

DENIED.)

The district court ordered Webb to pay, within 30 days, an

initial partial filing fee of $7.50, as per 28 U.S.C. §

1915(b)(1),(2). The district court did not err in its initial

order dismissing the complaint, because this amount had not been

paid and Webb had not informed the court that she had no money in

her prison account to pay it. However, Webb’s FED. R. CIV. P. 59(e)

motion and accompanying exhibits demonstrated that she had a zero

balance in her prison account for the 30 days following the

district court’s order and thus had no means with which to comply

with that order.

“In no event shall a prisoner be prohibited from bringing a

civil action ... for the reason that the prisoner has no assets and

no means by which to pay the initial partial filing fee.” 28 U.S.C.

§ 1915(b)(4). Under this provision, Webb should be permitted to

proceed IFP while remaining responsible for paying the full filing

fee through installment payments. See Norton v. Dimazana, 122 F.3d

286, 290-91 (5th Cir. 1998); Walp v. Scott, 115 F.3d 308, 310 (5th

Cir. 1997).

For the foregoing reasons, the judgment is VACATED and the

case is REMANDED for proceedings consistent with this opinion.

VACATED AND REMANDED; MOTIONS DENIED
EXHIBIT 32.2

GENAERA CORPORATION

CERTIFICATION OF

CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Genaera Corporation (the Company) on Form 10-Q for the period ended
September 30, 2006 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, John A. Skolas, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
| | --- | ---------------------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                    
|----------------------------------------------------
|                                                    
|/s/ John A. Skolas                                  
|John A. Skolas                                      
|Executive Vice President and Chief Financial Officer
|                                                    
|November 9, 2006
**Exhibit 31.1**

**Certification**

I, Jerome J. Gassen, President and Chief Executive Officer of Ameriana Bancorp,certify that: 

1. I have reviewed this Annual Report on Form 10-K of Ameriana Bancorp; 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of theregistrant as of, and for, the periods presented in this report; 

4. The registrant’s other certifying officer(s) and I areresponsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, includingits consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the endof the period covered by this report based on such evaluation; and 

(c) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting; and 

5. The registrant’s other certifyingofficer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing theequivalent functions): 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control overfinancial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. 

Date: March 28, 2007
IV 

114TH CONGRESS 

2D SESSION H. RES. 645 

Expressing the sense of the House that individuals captured by the United 

States for supporting the Islamic State of Iraq and the Levant should 

be detained at United States Naval Station, Guantanamo Bay, Cuba. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 15, 2016 

Mrs. WALORSKI (for herself, Mr. BYRNE, Mr. COFFMAN, Mr. FRANKS of Arizona, Mr. FLEMING, Mr. LAMBORN, Mr. AUSTIN SCOTT of Georgia, Mr. 

WILSON of South Carolina, and Mr. ZINKE) submitted the following resolution; which was referred to the Committee on Armed Services, and in 

addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such 

provisions as fall within the jurisdiction of the committee concerned 

RESOLUTION 

Expressing the sense of the House that individuals captured 

by the United States for supporting the Islamic State 

of Iraq and the Levant should be detained at United 

States Naval Station, Guantanamo Bay, Cuba. 

1 Resolved, That it is the sense of the House that— 

2 (1) the Islamic State of Iraq and the Levant 

3 (ISIL) has declared war on the United States; 

4 (2) the United States Armed Forces are cur5 rently engaged in combat operations against ISIL; 


srobinson on DSK5SPTVN1PROD with BILLS
2 

•HRES 645 IH 

1 (3) in conducting combat operations against 

2 ISIL, the United States has captured and detained 

3 individuals associated with ISIL and will likely cap4 ture and hold additional ISIL detainees; 

5 (4) following the horrific terrorist attacks on 

6 September 11, 2001, the United States determined 

7 that it would detain at United States Naval Station, 

8 Guantanamo Bay, Cuba, individuals who had en9 gaged in, aided, or abetted, or conspired to commit, 

10 acts of international terrorism, or acts in prepara11 tion therefor, that have caused, threaten to cause, or 

12 have as their aim to cause, injury to or adverse ef13 fects on the United States, its citizens, national se14 curity, foreign policy, or the economy; 

15 (5) members of ISIL captured by the United 

16 States during combat operations against ISIL meet 

17 such criteria for continued detention at United 

18 States Naval Station, Guantanamo Bay; and 

19 (6) all individuals captured by the United 

20 States during combat operations against ISIL that 

21 meet such criteria by their affiliation with ISIL 

22 must be detained outside the United States and its 

23 territories and should be transferred to United 

24 States Naval Station, Guantanamo Bay. 

Æ 


srobinson on DSK5SPTVN1PROD with BILLS
Item_5_1_12_MERS-CoV/ page 1

Annex 20

TERMINOLOGY: USE OF THE TERMS‘FETAL’, ‘FOETAL’, ‘FETUS’ AND ‘FOETUS’

Article 4.10.3.

Procedures for micromanipulation

The term “micromanipulated” covers several different procedures and a variety of specialised microsurgical instruments and other equipment may be used. However, from the standpoint of animal health, any cutting, penetrating or breaching of the integrity of the zona pellucida is an action that can alter the health status of an embryo. To maintain health status during and after micromanipulation, the following conditions should apply:

1.	Media

Any product of animal origin, including co-culture cells and media constituents, used in the collection or production of oocytes, embryos or other cells, and in their micromanipulation, culture, washing and storage should be free from pathogenic agents (including transmissible spongiform encephalopathy agents, sometimes called prions). All media and solutions should be sterilised by approved methods in accordance with the Manual of the IETS and handled in such a manner as to ensure that sterility is maintained. Antibiotics should be added to all fluids and media as recommended in the Manual of the IETS.

2.	Equipment

Equipment (e.g. microsurgical instruments which have direct contact with embryos) should either be of the single-use type (disposed of after each oocytes or embryos batch) or should be effectively sterilised between oocytes or embryos batch in accordance with recommendations in the Manual of the IETS.

3.	Nuclei for transplantation (“nuclear transfer”)

a)	Where it is intended to transplant nuclei derived from pre-hatching stage (i.e. zona pellucida intact) embryos, the parent embryos from which those nuclei are derived should fulfil the conditions of this chapter. Where nuclei derived from other types of donor cell (e.g. post-hatching stage embryos, embryonic,~~foetal~~ fetal and adult cells, including spermatozoa or spermatids for ICSI) are to be transplanted, the parent embryo,~~foetus~~ fetus or animal from which those donor cells originate, and the methods whereby they are derived, including cell culture, should comply with the relevant animal health standards recommended elsewhere in this *Terrestrial Code* and in the *Terrestrial Manual*.

b)	Where it is intended to transplant a nucleus into an intact oocyte (e.g. for ICSI), or into an enucleated oocyte (for nuclear transfer), those oocytes should be collected, cultured and manipulated in accordance with the recommendations in this chapter.

___________________________

*OIE Terrestrial Animal Health Standards Commission/September 2021*

Report of the Meeting of the WOAH Terrestrial Animal Health Standards Commission/February 2023	1
Breadcrumb

1. Home

2. Print 

3. Pdf 

4. Node 

5. Entity Print 

USDA Solicits Input on Petition to

Deregulate Corn Developed Using

Genetic Engineering

Print

Stakeholder Announcement
Contact:

Richard.S.Coker@usda.gov

WASHINGTON, [March 1, 2024] – The U.S. Department of Agriculture’s (USDA)

Animal and Plant Health Inspection Service (APHIS) is soliciting public input on a

petition submitted by Bayer U.S.-Crop Science (Bayer) to deregulate a corn cultivar

developed using genetic engineering. The cultivar is designated as MON95379. It

was modified to resist feeding damage caused by target lepidopteran pests,

including fall armyworm (Spodoptera frugiperda), sugarcane borer (diatraea

saccharalis), and corn earworm (Helicoverpa zea).  The input we receive during the

public comment period will help us identify issues and potential impacts we should

consider in our review and determine the appropriate environmental documents to

prepare to document our decision.  

We are evaluating MON95379 corn under USDA’s legacy regulations (formerly, 7

CFR § 340.6) because Bayer submitted the product for review prior to

implementation of our current biotechnology regulations. The legacy regulations

focused on whether a plant pest was used in the product development and if there

are potential increased plant pest risks compared to conventional counterparts.

Under the legacy regulations, APHIS first solicits public input on the petition for 60

days. The comments we receive on the petition aid the Agency in preparing

appropriate environmental documents. A second opportunity for public involvement

will come when we publish either a notice of availability of a draft environmental

assessment and draft plant pest risk assessment or a notice of intent to prepare an

environmental impact statement in the Federal Register.

The petition will be available for a 60-day public comment period.

Beginning Monday, March 4, members of the public will be able to submit comments

through May 3, 2024 at the link below. 

View FR Notice

View Petition (21.58 MB)

Submit a Public Comment
pennsyLvania 

DEPARTMENT OF ENVIRONMENTAL PROTECTION 

SECRETARY 

November 15, 2013 

Mr. Shawn M. Garvin 

Regional Administrator 

U.S. Enviromnental Protection Agency, Region III 

1650 Arch Street (Mail Code: 3RAOO) 

Philadelphia, P A 19103-2029 

Dear Mr. Garvin: 

Enclosed for your approval is a revision to Pennsylvania's State Implementation Plan (SIP) 

pertaining to the adoption by Allegheny County Health Department (ACHD) in June 2013 of 

regulations implementing Control Techniques Guidelines (CTGs) promulgated by the 

U.S. Enviromnental Protection Agency (EPA) in 2008 for Miscellaneous Metal and/or Plastic 

Parts Surface Coating Processes; Automobile and Light-Duty Truck Assembly Coatings; 

Miscellaneous Industrial Adhesives; and Fiberglass Boat Manufacturing Materials. The CTGs 

constitute Reasonably Available Control Technology (RACT) for the covered processes. The 

revision is identified as revision No. 74 to the Attaimnent and Maintenance Plan for ACHD's 

internal tracking. 

The ACHD is a local health agency organized under Local Health Administration Law, Act 315 

of August 24, 1951, P.L. 1304, as amended, whose powers and duties include the enforcement of 

laws relating to public health within Allegheny County. The ACHD has an air pollution control 

program that has been approved by the Department of Enviromnental Protection in accordance 

with Section 12 of the Air Pollution Control Act. 

I have enclosed a hard copy and a compact disc of the supplemental SIP submittal materials 

which consist of the Supplemental SIP submittal documents, documentation of public hearing 

and comment period, and the comment and response document. I certifY that the electronic files 

are exact duplicates of the hard copies. 

The Commonwealth followed all of the procedural requirements of the State's laws and 

constitution in conducting and completing the adoption/issuance of the SIP revision. 

Thank you for your attention to this matter. Should you have any questions concerning this SIP 

revision, please contact Joyce E. Epps, Director of Air Quality, bye-mail atjeepps@pa.govor 

by telephone at 717.787.9702. You may also contact James E. Thompson, Manager, Air Quality 

Program of the ACHD, bye-mail atjthompson@achd.netorbytelephone at 412.578.7963. 

Sincerely, 

. ~ (I {J ~~ 

E. Chris~e;Ab~:o yy Acting Secretary 

Enclosures 

Rachel Carson State Office Building 1 P.O. Box 2663·1 Harrisburg, PA 17105-2063 

717.787.2814 en Printed on Recycled Paper \673 www.depweb.state.pa.us 
Mr. Shawn M. Garvin 

cc: Joyce Epps 

James Thompson, ACHD 

Diana Esher, EPA Region III 

-2-
# C_2018341EN.01000801.xml

| 24.9.2018 | EN | Official Journal of the European Union | C 341/8 |
| --- | --- | --- | --- |

24.9.2018

EN

Official Journal of the European Union

C 341/8

---

Request for a preliminary ruling from the Administrativen sad Sofia-grad (Bulgaria) lodged on 12 July 2018 — GVC Services (Bulgaria) EOOD v Direktor na Direktsia ‘Obzhalvane i danachno-osiguritelna praktika’ Sofia

(Case C-458/18)

(2018/C 341/09)

Language of the case: Bulgarian

Referring court

Administrativen sad Sofia-grad

Parties to the main proceedings

Applicant: GVC Services (Bulgaria) EOOD

Defendant: Direktor na Direktsia ‘Obzhalvane i danachno-osiguritelna praktika’ Sofia

Questions referred

| 1. | Should Article 2(a)(i) of, in conjunction with Annex I, Part A(ab), to, Directive 2011/96/EU (1) be interpreted as meaning that the expression ‘companies incorporated under the law of the United Kingdom’ also covers companies incorporated in Gibraltar? |
| --- | --- |

1.

Should Article 2(a)(i) of, in conjunction with Annex I, Part A(ab), to, Directive 2011/96/EU (1) be interpreted as meaning that the expression ‘companies incorporated under the law of the United Kingdom’ also covers companies incorporated in Gibraltar?

| 2. | Should Article 2(a)(iii) of, in conjunction with Annex I, Part B, to, Directive 2011/96/EU be interpreted as meaning that the expression ‘corporation tax in the United Kingdom’ also covers the corporation tax that has to be paid in Gibraltar? |
| --- | --- |

2.

Should Article 2(a)(iii) of, in conjunction with Annex I, Part B, to, Directive 2011/96/EU be interpreted as meaning that the expression ‘corporation tax in the United Kingdom’ also covers the corporation tax that has to be paid in Gibraltar?

---

(1)  Council Directive 2011/96/EU of 30 November 2011 on the common system of taxation applicable in the case of parent companies and subsidiaries of different Member States (OJ 2011 L 345, p. 8).

---
Breadcrumb

1. Home

2. Print 

3. Pdf 

4. Node 

5. Entity Print 

Equine Infectious Anemia in Current

or Former Quarter Horse Racehorses

Print

Equine infectious anemia (EIA) is an untreatable blood-borne viral disease of horses.

It has been detected and controlled in the United States since the 1970s using a

diagnostic assay called the Coggins test. Over time, the prevalence of EIA in the U.S.

had been reduced to very low levels, estimated to be around 0.004% of the horse

population. Historically, EIA-positive horses were primarily found in untested or

undertested equine populations where natural transmission by biting flies occurred

within individual herds. Since 2017, a new high-risk population for EIA infection has

emerged: current or former Quarter Horse racehorses, many with ties to

unsanctioned (bushtrack) racing.

The primary method of spread in this population is the human-facilitated transfer of

EIA-contaminated blood or blood products from infected to uninfected horses. This is

called iatrogenic transmission. It is completely preventable through basic hygiene

and biosecurity measures. Common methods of iatrogenic transmission include:

Re-use of needles, syringes, or intravenous administration equipment between

horses,

Blood-contamination of multi-dose vials of injectable medication,

Illegal importation of blood or plasma products from other countries, and

Direct blood transfusion between horses for the purpose of increasing athletic

performance (blood-doping).
These unhygienic practices can also spread other blood-borne diseases between

horses, such as equine piroplasmosis (EP). To prevent further spread, current

Quarter Horse racehorses should be regularly tested for both EIA and EP throughout

their racing career. If you own current or former Quarter Horse racehorses and you

don’t know their status for these diseases, you should work with your veterinarian to

test for EIA and EP.

Learn more about EIA at www.aphis.usda.gov.
<PAGE>

EXHIBIT 32.2 - CFO 906 CERTIFICATION

     CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Interland, Inc. (the "Company") on Form
10-K for the period ending August 31, 2005 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Gonzalo Troncoso,
Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of
my knowledge:

1.    The Report fully complies with the requirements of Section 13(a) of the
      Securities Exchange Act of 1934; and

2.    The information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.

Date:  November 7, 2005                 /s/ Gonzalo Troncoso
                                        __________________________________
                                        Gonzalo Troncoso
                                        Executive Vice President and Chief
                                        Financial Officer